Hello choir! The leronlimab data including bio
Post# of 148263
(Total Views: 1610)
Posted On: 07/23/2021 12:36:17 PM
Hello choir!
The leronlimab data including biomarkers, dosage amount, dosage frequency, efficacy, etc. is expanding the CYDY knowledge-base exponentially because they have multiple trials across multiple diseases.
They have already proven efficacy in HIV, and have gotten really close to showing sufficient efficacy in Covid19 severe & critical cases even when hamstrung by regulators with only 2 doses. Soon the Brazil Covid19 trials will start, and utilize more doses, as well as IV administration for the critical cases. We will see quickly what that means to the efficacy numbers.
The P2 trials in Covid19 Longhaulers, mTNBC, NASH etc are data rich and point to a future in markets of huge size.
It has been obvious that now with any new P2 trial they are IMO going to be more productive, and with each new P3 trial they are IMO going to hit their endpoints because they understand the drug much better. It is remarkable to have a drug that may help in dozens of diseases.
I am so glad they have shown vision and resilience beyond one disease, beyond one trial at a time, and beyond one country!
The leronlimab data including biomarkers, dosage amount, dosage frequency, efficacy, etc. is expanding the CYDY knowledge-base exponentially because they have multiple trials across multiple diseases.
They have already proven efficacy in HIV, and have gotten really close to showing sufficient efficacy in Covid19 severe & critical cases even when hamstrung by regulators with only 2 doses. Soon the Brazil Covid19 trials will start, and utilize more doses, as well as IV administration for the critical cases. We will see quickly what that means to the efficacy numbers.
The P2 trials in Covid19 Longhaulers, mTNBC, NASH etc are data rich and point to a future in markets of huge size.
It has been obvious that now with any new P2 trial they are IMO going to be more productive, and with each new P3 trial they are IMO going to hit their endpoints because they understand the drug much better. It is remarkable to have a drug that may help in dozens of diseases.
I am so glad they have shown vision and resilience beyond one disease, beyond one trial at a time, and beyond one country!
(14)
(0)CytoDyn Inc (CYDY) Stock Research Links
There are no guarantees in investing. No one should consider these pages or posts to be financial advice. Everyone has a responsibility to verify and thoroughly learn more than what is referenced or written here, and everyone must take responsibility for their own investing decisions.
Scroll down for more posts ▼